Viral vector targeting

Current Opinion in Biotechnology

Volumn 10, Issue 5, 1999, Pages 454-457

  Peng, Kah Whye ^a   Russell, Stephen J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COAT PROTEIN; PROTEINASE; VIRUS VECTOR;

ADENOVIRUS; BINDING SITE; CROSS LINKING; ENZYME ACTIVATION; GENE TARGETING; GENETIC TRANSCRIPTION; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; RECEPTOR BINDING; RETROVIRUS; SHORT SURVEY; VIRUS REPLICATION;

EID: 0032861707     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(99)00009-9     Document Type: Review

References (48)

1. Schellingerhout D, Bogdanov A Jr., Marecos E, Spear M, Breakefield X, Weissleder R Mapping the in vivo distribution of herpes simplex virions. Hum Gene Ther. 9:1998;1543-1549.
2. Yip YL, Hawkins NJ, Smith G, Ward RL Biodistribution of filamentous phage-Fab in nude mice. J Immunol Methods. 225:1999;171-178.
3. Lu Y, Carraher J, Zhang Y, Armstrong J, Lerner J, Rogers WP, Steiner MS Delivery of adenoviral vectors to the prostate for gene therapy. Cancer Gene Ther. 6:1999;64-72.
4. Valsesia-Wittmann S, Morling FJ, Nilson BH, Takeuchi Y, Russell SJ, Cosset FL Improvement of retroviral retargeting by using amino acid spacers between an additional binding domain and the N terminus of Moloney murine leukemia virus SU. J Virol. 70:1996;2059-2064.
5. Ager S, Nilson BH, Morling FJ, Peng KW, Cosset FL, Russell SJ Retroviral display of antibody fragments: interdomain spacing strongly influences vector infectivity. Hum Gene Ther. 7:1996;2157-2164.
6. Watkins SJ, Mesyanzhinov VV, Kurochkina LP, Hawkins RE The 'adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery. Gene Ther. 4:1997;1004-1012.
7. Laquerre S, Anderson DB, Stolz DB, Glorioso JC Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells. J Virol. 72:1998;9683-9697.
8. Yang Q, Mamounas M, Yu G, Kennedy S, Leaker B, Merson J, Wong-Staal F, Yu M, Barber JR Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for gene therapy. Hum Gene Ther. 9:1998;1929-1937.
9. Bartlett JS, Kleinschmidt J, Boucher RC, Samulski RJ Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody. Nat Biotechnol. 17:1999;181-186.
10. Douglas JT, Rogers BE, Rosenfield ME, Micheal SI, Feng M, Curiel DT Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol. 14:1996;1574-1578.
11. Wickham TJ, Lee GM, Titus JA, Sconocchia G, Bakacs T, Kovesdi I, Segal DM Targeted adenovirus-mediated gene delivery to T cells via CD3. J Virol. 71:1997;7663-7669.
12. Ohno K, Sawai K, Lijima Y, Levin B, Meruelo D Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A. Nat Biotechnol. 15:1997;763-767.
13. Ohno K, Meruelo D Retrovirus vectors displaying the IgG-binding domain of protein A. Biochem Mol Med. 62:1997;123-127.
14. + lymphoid cells. Gene Ther. 5:1998;209-217.
15. Schnierle BS, Stitz J, Bosch V, Nocken F, Merget-Millitzer H, Engelstadter M, Kurth R, Groner B, Cichutek K Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells. Proc Natl Acad Sci USA. 94:1997;8640-8645.
16. Schnell MJ, Johnson JE, Buonocore L, Rose JK Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell. 90:1997;849-857.
17. Hall FL, Gordon EM, Wu L, Zhu NL, Skotzko MJ, Starnes VA, Anderson WF Targeting retroviral vectors to vascular lesions by genetic engineering of the MoMLV gp70 envelope protein. Hum Gene Ther. 8:1997;2183-2192.
18. Cosset F-L, Morling FJ, Takeuchi Y, Weiss RA, Collins MKL, Russell SJ Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol. 69:1995;6314-6322.
19. Benedict CA, Tun RY, Rubinstein DB, Guillaume T, Cannon PM, Anderson WF Targeting retroviral vectors to CD34-expressing cells: binding to CD34 does not catalyze virus-cell fusion. Hum Gene Ther. 10:1999;545-557.
20. Cosset F-L, Russell SJ Targeting retrovirus entry. Gene Ther. 3:1996;946-956.
21. Jiang A, Chu TH, Nocken F, Cichutek K, Dornburg R Cell-type-specific gene transfer into human cells with retroviral vectors that display single-chain antibodies. J Virol. 72:1998;10148-10156.
22. Hatziioannou T, Valsesia-Wittmann S, Russell SJ, Cosset FL Incorporation of fowl plague virus hemagglutinin into murine leukemia virus particles and analysis of the infectivity of the pseudotyped retroviruses. J Virol. 72:1998;5313-5317.
23. Wickham TJ, Roelvink PW, Brough DE, Kovesdi I Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat Biotechnol. 14:1996;1570-1573.
24. Vigne E, Mahfouz I, Dedieu JF, Brie A, Perricaudet M, Yeh P RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J Virol. 73:1999;5156-5161.
25. Chadwick MP, Morling FJ, Cosset FL, Russell SJ Modification of retroviral tropism by display of IGF-I. Mol Biol. 285:1999;485-494.
26. Fielding AK, Maurice M, Morling FJ, Cosset FL, Russell SJ Inverse targeting of retroviral vectors: selective gene transfer in a mixed population of hematopoietic and nonhematopoietic cells. Blood. 91:1998;1802-1809.
27. Snitkovsky S, Young JA Cell-specific viral targeting mediated by a soluble retroviral receptor-ligand fusion protein. Proc Natl Acad Sci USA. 95:1998;7063-7068.
28. Miller CR, Buchsbaum DJ, Reynolds PN, Douglas JT, Gillespie GY, Mayo MS, Raben D, Curiel DT Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res. 15:1998;5738-5748.
29. Von Seggern DJ, Chiu CY, Fleck SK, Stewart PL, Nemerow GR A helper-independent adenovirus vector with E1, E3, and fiber deleted: structure and infectivity of fiberless particles. J Virol. 73:1999;1601-1608.
30. MacKrell AJ, Soong NW, Curtis CM, Anderson WF Identification of a subdomain in the Moloney murine leukemia virus envelope protein involved in receptor binding. J Virol. 70:1996;1768-1774.
31. Morling FJ, Peng KW, Cosset F-L, Russell SJ Masking of retroviral envelope functions by oligomerizing polypeptide adaptors. Virology. 234:1997;51-61.
32. Peng KW, Morling FJ, Cosset F-L, Murphy G, Russell SJ A gene delivery system activatable by disease-associated matrix metalloproteinases. Hum Gene Ther. 8:1997;729-738.
33. Peng KW, Morling FJ, Cosset F-L, Russell SJ Retroviral gene delivery system activatable by plasmin. Tumor Targeting. 3:1998;112-120.
34. Peng KW, Vile RG, Cosset F-L, Russell SJ Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors. Gene Ther. 6:1999;1552-1557. A first report on a protease-targeted retroviral vector to preferentially target gene delivery to one cell type in a mixed cell population in vitro and to selectively transduce the protease-rich tumor xenograft in vivo.
35. Miller N, Whelan J Progress in transcriptionally targeted and regulatable vectors for genetic therapy. Hum Gene Ther. 8:1997;803-815.
36. Vile RG, Sunassee K, Diaz RM Strategies for achieving multiple layers of selectivity in gene therapy. Mol Med Today. 4:1998;84-92.
37. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 274:1996;373-376.
38. Coffey MC, Strong JE, Forsyth PA, Lee PW Reovirus therapy of tumors with activated Ras pathway. Science. 282:1998;1332-1334.
39. Toda M, Rabkin SD, Martuza RL Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther. 9:1998;2177-2185.
40. Toda M, Rabkin SD, Kojima H, Martuza RL Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther. 10:1999;385-393.
41. Buchholz CJ, Peng KW, Morling FJ, Zhang J, Cosset FL, Russell SJ In vivo selection of protease cleavage sites from retrovirus display libraries. Nat Biotechnol. 16:1998;951-954. A first report on the generation of a replication-competent Moloney MLV library displaying EGF and random protease cleavage site between EGF and MLV-envelope. Furin-sensitive viruses were selected from the library.
42. Arap W, Pasqualini R, Ruoslahti E Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 279:1998;377-380.
43. Samoylova TI, Smith BF Elucidation of muscle-binding peptides by phage display screening. Muscle Nerve. 22:1999;460-466.
44. Larocca D, Kassner PD, Witte A, Ladner RC, Pierce GF, Baird A Gene transfer to mammalian cells using genetically targeted filamentous bacteriophage. FASEB J. 6:1999;727-734.
45. Poul MA, Marks JD Targeted gene delivery to mammalian cells by filamentous bacteriophage. J Mol Biol. 288:1999;203-211.
46. Xia D, Henry LJ, Gerard RD, Deisenhofer J Crystal structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1.7 A resolution. Structure. 2:1994;1259-1270.
47. Fass D, Harrison SC, Kim PS Retrovirus envelope domain at 1.7 angstrom resolution. Nat Struct Biol. 3:1996;465-469.
48. Kayman SC, Park H, Saxon M, Pinter A The hypervariable domain of the murine leukemia virus surface protein tolerates large insertions and deletions, enabling development of a retroviral particle display system. J Virol. 73:1999;1802-1808. This paper reports that the hypervariable domain of ecotropic MLV envelope glycoprotein can tolerate insertions of single chain antibodies. Chimeric envelopes were folded correctly and expressed. Functional viral particles that could bind to the targeted antigen were produced.